Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial.

Blood - 1 Feb 2004

Kemmeren Jeanet M, Algra Ale, Meijers Joost C M, Tans Guido, Bouma Bonno N, Curvers Joyce, Rosing Jan, Grobbee Diederick E

Abstract excerpt

A plausible mechanism to explain thrombotic risk differences associated with the use of second- and third-generation oral contraceptives (OCs), particularly in carriers of factor V(Leiden), is still lacking. In a double-blind trial, 51 women without and 35 women with factor V(Leiden) were randomized to either a second- (30 microg ethinylestradiol/150 microg levonorgestrel) or third- (30 microg...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Factor V

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to APC gene

Share to Mutation

Share to Protein C

Share to Risk Factors

Share to Thrombosis

Source

Identifiers

PMID: 14551147
DOI: 10.1182/blood-2003-04-1285

Genes

APC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial.PMID 14551147Read ↗

Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.Semantic proximity Read ↗

The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk.Semantic proximity Read ↗

Pharmacogenetic aspects of the use of oral contraceptives and the risk of thrombosis.Semantic proximity Read ↗

Hormonal contraception, thrombosis and age.Semantic proximity Read ↗

Oral contraceptives and the risk of thrombosis and atherosclerosis.Semantic proximity Read ↗

Sensitivity to activated protein C during the menstrual cycle in women with and without factor VLeiden.Semantic proximity Read ↗

Factor V Leiden: should all women be screened prior to commencing the contraceptive pill?Semantic proximity Read ↗

[Screening for factor V Leiden mutation in women using combined hormonal contraceptives or hormone replacement therapy].Semantic proximity Read ↗

The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC).Semantic proximity Read ↗

[From pill to pill: oral contraception, venous thrombosis and coagulation disorders].Semantic proximity Read ↗

[Deep venous thrombosis associated with the taking of oral contraceptives: the existence of Leiden factor V?].Semantic proximity Read ↗

Oral contraceptives and screening for factor V Leiden.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.